A Phase 4 interventional study of Glimepiride and Metformin in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Terminated at 34 sites in 5 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2019-10-09.
Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 151 studies testing liraglutide in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 1 of them phase 3. Liraglutide · Diabetes Mellitus, Type 2.
Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, this one is the 47th largest by enrollment, is one of 13 that started in 2014, is one of 48 in phase 4, and was the 94th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →6 of the 151 studies testing liraglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 25–70
Mansa · Sites in United States
Ages 10+
Biolingus · Sites in Hong Kong
Ages 18–65
RenJi Hospital · Sites in China
Ages 18–65
University of Virginia · Sites in United States
Ages 21–60 · Healthy volunteers
By country, each count listing its studies:
Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
151 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 21 · Phase 3 46 · Phase 4 48
First in 1999; this study’s year is marked. 13 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 192 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 62 across the 151 interventional studies. Of the 127 that completed or were terminated, 52 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
75 of 151 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 115th largest by enrollment of the 232 interventional ones that give a count, is one of 8 that started in 2014, is one of 33 in phase 4, and was the 105th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
1 of the studies testing liraglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03883412University of VirginiaEffect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007) | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, from their registry updates:
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to compare the benefits and risks associated with the use of 2 treatment strategies to lower blood sugar in participants aged 65 and older with T2DM. One strategy is based on the use of oral and injectable medications that only reduce blood sugar (glucose) when it is high. The other strategy is based on non-glucose dependent agents. The trial will last up to 72 weeks for each participant.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have been treated for at least 3 months prior to the study entry with any of the following treatment options:
Effective or maximally-tolerated doses of metformin, dipeptidyl-peptidase-4 (DPP-4) inhibitor, thiazolidinedione, or acarbose used in monotherapy or in dual combination. The following doses are considered to be effective:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants may receive oral and injectable (glucagon-like peptide-1 receptor agonists \[GLP-1 RA\]) therapies that exert a glucose-dependent mode of action. Medications allowed in this arm include: metformin, pioglitazone, acarbose, linagliptin, sitagliptin, liraglutide, exenatide once weekly (QW), and exenatide twice daily (BID). Choice of therapy is based on investigator's discretion. Treatment used in label. Treatment may last up to 72 weeks.
Drug: Metformin · Drug: Pioglitazone · Drug: Acarbose · Drug: Linagliptin · Drug: Sitagliptin · Drug: Liraglutide · Drug: Exenatide once weekly (QW) · Drug: Exenatide twice daily (BID)
Participants will receive glimepiride and may receive basal insulin glargine as a first line injectable therapy. Medications allowed in this arm include: glimepiride, metformin, pioglitazone, acarbose, linagliptin, sitagliptin and basal insulin glargine. Choice of therapy is based on investigator's discretion. Treatment used in label. Insulin glargine is titrated according treatment algorithm. Treatment may last up to 72 weeks.
Drug: Glimepiride · Drug: Metformin · Drug: Pioglitazone · Drug: Acarbose · Drug: Linagliptin · Drug: Sitagliptin · Drug: Insulin Glargine
Administered orally
Administered orally
Administered orally
Administered orally
Administered orally
Administered orally
Administered subcutaneously (SC)
Administered SC
Administered SC
Administered SC
Percentage of Participants Achieving and Maintaining Individualized Glycated Hemoglobin A1c (HbA1c) Targets Without Clinically Significant Hypoglycemia
Failed to reach and maintain HbA1c target, without clinically significant hypoglycemia, is defined as having 2 consecutive HbA1c \> upper limit of HbA1c target over 12 weeks starting from Week 24 for participants with HbA1c data beyond Week 24, or Week 24 HbA1c \> upper limit of HbA1c target for participants without HbA1c data beyond Week 24. Clinically significant hypoglycemia is defined as any severe hypoglycemia or repeated hypoglycemia interrupting participants activities or sleep and associated with blood glucose ≤3.9 millimole per liter (mmol/L), or repeated asymptomatic hypoglycemia associated with blood glucose \<3.0 mmol/L. Success is defined as lacking of failure.
Time frame: Baseline to last participant visit (up to 72 weeks)
Percentage of Participants Requiring Alternative Treatment Due to Glycemic Failure of First Line Injectable Therapy
Time frame: Baseline to last participant visit (up to 72 weeks)
Number of Participants With Total Hypoglycemia and Other Categories of Hypoglycemia
Time frame: Baseline to last participant visit (up to 72 weeks)
Change From Baseline of Urinary Albumin to Creatinine Ratio
The Urinary Albumin to Creatinine Ratio is used in addition to Estimated Glomerular Filtration Rate (eGFR) to measure the incidence and progression of diabetic kidney disease.
Time frame: Baseline, Week 72
Change From Baseline in Body Mass Index (BMI)
Time frame: Baseline, Week 72
Change From Baseline of Estimated Glomerular Filtration Rate (eGFR)
The eGFR is used in addition to the Urinary Albumin to Creatinine Ratio to measure the incidence and progression of diabetic kidney disease.
Time frame: Baseline, Week 72
Change From Baseline in Adult Low Blood Sugar Survey (ALBSS) Score
Time frame: Baseline, Week 72
Change From Baseline in European Quality of Life-5 Dimensions 5 Levels (EQ-5D-5L) Score
Time frame: Baseline, Week 72
Change From Baseline in Mini-mental State Examination (MMSE) Score
Time frame: Baseline, Week 72
| Milestone | Strategy A (Glucose-Dependent) | Strategy B (Reference) |
|---|---|---|
| Started | 99 | 93 |
| Received at least one dose of study drug | 98 | 93 |
| Completed | 14 | 15 |
| Not completed | 85 | 78 |
| Withdrew: Lack of efficacy | 18 | 29 |
| Withdrew: Protocol violation | 7 | 7 |
| Withdrew: Withdrawal by subject | 5 | 7 |
| Withdrew: Adverse event | 5 | 2 |
| Withdrew: No reason provided | 4 | 2 |
| Withdrew: Death | 2 | 0 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Study terminated by sponsor | 43 | 30 |
| Withdrew: Lost to follow-up | 1 | 0 |
Failed to reach and maintain HbA1c target, without clinically significant hypoglycemia, is defined as having 2 consecutive HbA1c \> upper limit of HbA1c target over 12 weeks starting from Week 24 for participants with HbA1c data beyond Week 24, or Week 24 HbA1c \> upper limit of HbA1c target for participants without HbA1c data beyond Week 24. Clinically significant hypoglycemia is defined as any severe hypoglycemia or repeated hypoglycemia interrupting participants activities or sleep and associated with blood glucose ≤3.9 millimole per liter (mmol/L), or repeated asymptomatic hypoglycemia associated with blood glucose \<3.0 mmol/L. Success is defined as lacking of failure.
| percentage of participants | Strategy A (Glucose-Dependent) | Strategy B (Reference) |
|---|---|---|
| Percentage of Participants Achieving and Maintaining Individualized Glycated Hemoglobin A1c (HbA1c) Targets Without Clinically Significant Hypoglycemia | 64.5 (54.4 to 73.4) | 54.9 (44.6 to 64.9) |
| percentage of participants | Strategy A (Glucose-Dependent) | Strategy B (Reference) |
|---|---|---|
| Percentage of Participants Requiring Alternative Treatment Due to Glycemic Failure of First Line Injectable Therapy | 21 | 13 |
| Participants | Strategy A (Glucose-Dependent) | Strategy B (Reference) |
|---|---|---|
| Total Hypoglycemia | 10 | 50 |
| Severe Hypoglycemia | 0 | 0 |
| Clinically Significant Hypoglycemia | 0 | 1 |
| Symptomatic Hypoglycemia | 5 | 34 |
| Asymptomatic Hypoglycemia | 8 | 30 |
| Probable Symptomatic Hypoglycemia | 0 | 7 |
| Unspecified Hypoglycemia | 2 | 7 |
| Relative Hypoglycemia | 1 | 6 |
| Nocturnal Hypoglycemia | 4 | 10 |
The Urinary Albumin to Creatinine Ratio is used in addition to Estimated Glomerular Filtration Rate (eGFR) to measure the incidence and progression of diabetic kidney disease.
| milligram per millimole (mg/mmol) | Strategy A (Glucose-Dependent) | Strategy B (Reference) |
|---|---|---|
| Change From Baseline of Urinary Albumin to Creatinine Ratio | 1.85 ± 22.99 | 1.85 ± 16.46 |
| kilogram per square meter (kg/m^2) | Strategy A (Glucose-Dependent) | Strategy B (Reference) |
|---|---|---|
| Change From Baseline in Body Mass Index (BMI) | -0.47 ± 1.56 | 0.20 ± 2.91 |
The eGFR is used in addition to the Urinary Albumin to Creatinine Ratio to measure the incidence and progression of diabetic kidney disease.
| milliliter per minute/1.73 square meter | Strategy A (Glucose-Dependent) | Strategy B (Reference) |
|---|---|---|
| Change From Baseline of Estimated Glomerular Filtration Rate (eGFR) | -5.00 ± 13.64 | -5.88 ± 10.95 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Strategy A (Glucose-Dependent) | — | 15/98 (15.3%) | 82/98 (83.7%) |
| Strategy B (Reference) | — | 14/93 (15.1%) | 74/93 (79.6%) |
| Event | Strategy A (Glucose-Dependent) | Strategy B (Reference) |
|---|---|---|
| Atrial fibrillationCardiac disorders | 0/98 | 2/93 |
| Myocardial infarctionCardiac disorders | 0/98 | 2/93 |
| Cerebrovascular accidentNervous system disorders | 2/98 | 0/93 |
| Cardiac failure congestiveCardiac disorders | 1/98 | 1/93 |
| Lower gastrointestinal haemorrhageGastrointestinal disorders | 0/98 | 1/93 |
| AppendicitisInfections and infestations | 0/98 | 1/93 |
| PneumoniaInfections and infestations | 0/98 | 1/93 |
| Respiratory tract infectionInfections and infestations | 0/98 | 1/93 |
| ContusionInjury, poisoning and procedural complications | 0/98 | 1/93 |
| Muscle ruptureInjury, poisoning and procedural complications | 0/98 | 1/93 |
| Event | Strategy A (Glucose-Dependent) | Strategy B (Reference) |
|---|---|---|
| NasopharyngitisInfections and infestations | 10/98 | 16/93 |
| DiarrhoeaGastrointestinal disorders | 12/98 | 6/93 |
| Back painMusculoskeletal and connective tissue disorders | 9/98 | 11/93 |
| Vitamin d deficiencyMetabolism and nutrition disorders | 9/98 | 3/93 |
| Urinary tract infectionInfections and infestations | 3/98 | 8/93 |
| Upper respiratory tract infectionInfections and infestations | 3/98 | 7/93 |
| NauseaGastrointestinal disorders | 7/98 | 3/93 |
| HeadacheNervous system disorders | 7/98 | 1/93 |
| Oedema peripheralGeneral disorders | 1/98 | 6/93 |
| OedemaGeneral disorders | 6/98 | 0/93 |
All randomized participants.
| Age, Continuous(years) | Strategy A (Glucose-Dependent) | Strategy B (Reference) | Total |
|---|---|---|---|
| Mean | 70.7 ± 5.3 | 70.7 ± 4.4 | 70.7 ± 4.9 |
| Sex: Female, Male(Participants) | Strategy A (Glucose-Dependent) | Strategy B (Reference) | Total |
|---|---|---|---|
| Female | 43 | 34 | 77 |
| Male | 56 | 59 | 115 |
| Ethnicity (NIH/OMB)(Participants) | Strategy A (Glucose-Dependent) | Strategy B (Reference) | Total |
|---|---|---|---|
| Hispanic or Latino | 35 | 32 | 67 |
| Not Hispanic or Latino | 63 | 59 | 122 |
| Unknown or Not Reported | 1 | 2 | 3 |
| Race (NIH/OMB)(Participants) | Strategy A (Glucose-Dependent) | Strategy B (Reference) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 6 | 10 | 16 |
| White | 93 | 81 | 174 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Strategy A (Glucose-Dependent) | Strategy B (Reference) | Total |
|---|---|---|---|
| Austria | 18 | 14 | 32 |
| Puerto Rico | 23 | 16 | 39 |
| United States | 29 | 35 | 64 |
| United Kingdom | 10 | 11 | 21 |
| Germany | 19 | 17 | 36 |
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
The record gives a start of Feb 2014, a primary completion of Oct 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2016, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liraglutide